-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
In Brief for May 28, 2025
The US FDA grants accelerated approval to telisotuzumab vedotin-tllv for advanced NSCLC with high c-Met overexpression.
-
The Elephant in the Room: Addressing Oncology’s Carbon Footprint
From travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy.
-
Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy
Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC.
-
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC
Research team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting.
-
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going
Pioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC.
-
In Brief for May 14, 2025
Pembrolizumab-chemotherapy combo receives Canadian approval for first-line treatment of malignant pleural mesothelioma.
-
A Real Tail in These Curves: A Look at Advances and Future Directions in SCLC
During a recent address at SCLC 2025, Dr. Charles Rudin discussed the progress being made in reducing the incidence of small cell lung cancer and in treating it.
-
COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities
Dr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events.
-
Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression
Dr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib.
-
Up in the Air: A Patient’s Perspective on Navigating Lung Cancer Treatment During One of the Most Devastating Wildfires in US History
Lynn Lieberman was already in a fight against lung cancer, but she faced a second battle when the Los Angeles wildfires spread throughout her community.